Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | APLT |
---|---|---|
09:32 ET | 15219 | 8.5 |
09:34 ET | 1224 | 8.38 |
09:36 ET | 1852 | 8.355 |
09:38 ET | 5370 | 8.34 |
09:39 ET | 1000 | 8.41 |
09:41 ET | 8947 | 8.39 |
09:43 ET | 204 | 8.39 |
09:45 ET | 5304 | 8.48 |
09:48 ET | 7616 | 8.51 |
09:50 ET | 2300 | 8.49 |
09:52 ET | 1700 | 8.45 |
09:54 ET | 3161 | 8.46 |
09:56 ET | 8287 | 8.53 |
09:57 ET | 2222 | 8.475 |
09:59 ET | 1029 | 8.5 |
10:01 ET | 3304 | 8.505 |
10:03 ET | 22661 | 8.54 |
10:06 ET | 621 | 8.515 |
10:08 ET | 3673 | 8.48 |
10:10 ET | 27754 | 8.45 |
10:12 ET | 2558 | 8.47 |
10:14 ET | 4070 | 8.45 |
10:15 ET | 100 | 8.43 |
10:17 ET | 4428 | 8.47 |
10:19 ET | 1000 | 8.42 |
10:21 ET | 1679 | 8.41 |
10:24 ET | 4479 | 8.43 |
10:26 ET | 3750 | 8.465 |
10:28 ET | 13795 | 8.4 |
10:30 ET | 1348 | 8.37 |
10:32 ET | 8777 | 8.36 |
10:33 ET | 500 | 8.37 |
10:35 ET | 1299 | 8.375 |
10:37 ET | 1846 | 8.36 |
10:39 ET | 6496 | 8.41 |
10:42 ET | 4200 | 8.4 |
10:44 ET | 276 | 8.39 |
10:46 ET | 6418 | 8.36 |
10:48 ET | 400 | 8.35 |
10:50 ET | 3495 | 8.37 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Applied Therapeutics Inc | 965.9M | -5.5x | --- |
AnaptysBio Inc | 981.3M | -5.1x | --- |
IGM Biosciences Inc | 940.8M | -4.6x | --- |
Sana Biotechnology Inc | 949.9M | -3.9x | --- |
Autolus Therapeutics PLC | 926.0M | -3.1x | --- |
Cullinan Therapeutics Inc | 1.0B | -5.6x | --- |
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $965.9M |
---|---|
Revenue (TTM) | $-333.0K |
Shares Outstanding | 114.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.04 |
EPS | $-1.52 |
Book Value | $-0.20 |
P/E Ratio | -5.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.